Bio B2B 〉 Selective Search Results
Your Selection Setting ：In Vitro Diagnostic；
Selective Search Results :
On-Market Product 40 record(s)；
Personal Genetics Testing
Whole Genome ScanPotential ProbeSociabilityLinguisticMemoryCreativityExecutionSelf-ControlSentimentalityAttentivenessComprehensionSport PhysiologyMusicDrawingMathematical AbilityUnipro DNA Testing
PixoTest Blood Glucose Monitoring System
The PixoTest Blood Glucose Monitoring System is a globally exclusive meter-free In Vitro Diagnostic blood glucose monitoring system. With unique all-in-one test strips, users only need to bring a small catridge and his/her own smartphone to measure his/her blood glucose level. Test Readings are recorded automatically and sync to the cloud. It allows users to do their self-management anytime and
AmCAD-UT® Detection uses statistical pattern recognition and quantification methods to perform analytical processing of images. The physician may process the image for detection of sonographic characteristics (i.e., hyperechoic foci, echogenicity, texture, margin, anechoic areas, taller than wide, tumor shape, and tumor size) with assistance of AmCAD-UT® Detection. AmCAD-UT® Detection provides
NANBASE C-96 V4.0
NANBASE C-96 V4.0 is a forth generation enzyme immunoassay diagnostic kit for in-vitro qualitative detection and screening assay of Antibody to Hepatitis C virus (anti-HCV) in human serum or plasma.
Human Papillomavirus Screening, HPV Screening
SOFIVA GENOMICS offers Roche's cobas® HPV screening test, which is the first and only screening test approved to replace pap smears as a primary screening tool for cervical cancerNote 1 by the FDAs in both Taiwan and the US. This test screens for many high-risk types of HPV, including types 16 and 18, as well as 12 other high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).Provides
Now with CRC Protect, you can offer all of your patients convenient and accurate CRC screening with a simple blood test.Using just a blood sample, the CRC Protect can detect precancerous cells before they become tumors. CRC Protect helps you determine next steps for your patients and gives you confidence that you are screening with an accurate, clinically proven test for early detection of colorectal
SpinScan Microarray Scanner
SpinScan Microarray Scanner, is based on a modified optical pickup head, akin to well establish DVD technology to the molecular diagnostic market. It is the only reader where the 6 slides can be read at one time. Moreover, the platform is easily scalable simply by faster rotation scan with corresponding upgrade in detection.We're now working on adding more integration to the modified
Comprehensive Genomic Profiling Service
ACTOnco®+ : Comprehensive Genomic Profiling Service is used to examine the genetic mutations in cancer patients for their personalized treatment plan. It is a breakthrough product to support current clinical guideline. Using next generaion sequencing (NGS) to test 440 cancer-related genes, ACTOnco®+ won Symbol of National Quality (SNQ) and National Innovative Award in Taiwan, Frost &
Preventive Genetic Testing
Know your inherent genetic risk for various conditions. Test results provide information that will help guide a person's future medical care.Disease Genetic TestingCancer Risk AssessmentStress-Relief kit
SURASE B-96 (TMB)
SURASE B-96 (TMB) is a fast test for the qualitative detection of the presence of HBsAg in serum or plasma (heparin,citrate or EDTA) specimen. The test utilizes monoclonal and polyclonal (anti-guinea pig) antibodies to selectively detectelevated levels of HBsAg in serum or plasma.
Newborn genetic screening
We developed an easy way to detect certain genetic diseases, for example, congenital central hypoventilation syndrome (CCHS) or sensorineural hearing loss, and congenital infections like CMV by using neonatal heel blood at the very beginning of their lives for good outcomes by medical intervention as early as possible.Every year, between 600 and 2,000 newborns in Taiwan are diagnosed with sensorineural
DNA Genetic Cancer Risk Test
About the SMSEQ® Platform and CellMax-DNA Genetic Cancer Test CellMax Life's SMSEQ® platform has an analytical specificity of ≥99.999%. This patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and comprehensive genetic cancer risk test, utilizing an expanded 98 gene panel using personal DNA from a
Targeted Genomic Profiling Service
ACTDrug®+ : Targeted Genomic Profiling Service is used to examine the genetic mutations in cancer patients for their personalized treatment plan. It is a breakthrough product to support current clinical guideline. Using next generation sequencing (NGS) to test 40 druggable genes.
Healthcare Genetic Testing
Never-AgeWith strong and powerful scientific evidences, our ”Beauty Reprogramming Genetic Testing Package” could make you realize your 5 healthy skin factors and help you choose the skin care products suitable for you without wasting money on un-efficient products. Weight ManagementThe personalized dieting programThe personalized fitness management
MyGene Cancer Monitor
The occurrence of cancer can be caused by the mutant of DNA within cells that lead to cell abnormality. Therefore, we can identify this mutant DNA which called circulating tumor DNA (ctDNA).The level of ctDNA is changeful. It depends on the progress of the disease, the size of tumor and influencing the level of ctDNA. Therefore, we can detect the ctDNA to provide an early warning of recurrence and
AmCAD-US is a software package designed to quantify and visualize the backscatter statistics contained in ultrasound image data obtained from an FDA-cleared general purpose ultrasound system. The device provides dual mode images, including conventional B-mode ultrasound image in gray scale and color-mapped US (ultrasound structure) mode image. The US-mode provides a means for viewing and
ANTISURASE B-96 (TMB) is an enzyme immunoassay diagnostic kit for in vitro qualitative detection of Antibody to Hepatitis B surface antigen (Anti-HBs) in human serum or plasma (heparin, citrate or EDTA). The test can be used prior and after hepatitis B vaccination to assess the immune status as well as an aid to diagnose and monitor infections by hepatitis B virus.
References:1.Ross et al, Cancer Epidemiology Biomarkers Prevention, 20082.Lin et al, Annals of Internal Medicine, 20083.Schaeffer et al, Journal of Urology, 20114.Americal Urology Association data5.West, Jin, JAMA Oncology, June 20156.Loeb El al, Journal of Urology, Apr 20157.Fong et al American Society of Clinical Onology, 20188.Chen et al, Asian Journal of Urology, 2014
Fusion Gene Testing
ACTFusionTM : Fusion Gene Testing is used to examine the genetic mutations in cancer patients for their personalized treatment plan. It is a breakthrough product to support current clinical guideline. Using next generation sequencing (NGS) to test 31 fusion genes and 182 transcripts, ACTFusionTM provides opportunities to use new targeted therapy across multiple cancers.
MyGene Cancer Screening
Most of DNA in the body is located within cells. DNA is released during cell death into the bloodstream as cell free DNA. Dying tumor cells also release cell free DNA into the bloodstream called circulating tumor DNA (ctDNA). With the most advanced next generation sequencing, technicians can obtain genetic information from tumor cells to further analyze the possible types of cancer. The advantage
Drug MetabolismGenetic Test of cytochrome P450 for drug metabolism. Cancer TherapyBy performing genetic tests on the cancer cells and on normal cells, doctors may be able to customize treatment to each patient's needs. Matching patients with treatments that are more likely to be more effective and cause fewer side effects.Predicting the risk of recurrence, which is the return of cancer.AntidepressantsThe
HEPAVASE MA-96 (TMB)
HEPAVASE MA-96 (TMB) is a fast test for the qualitative detection of IgM antibody to Hepatitis A virus in serum or plasma (heparin, citrate or EDTA) specimens. This is an enzyme linked immunosorbent assay (ELISA) which utilizes Anti-human IgM on microtiter wells as solid phase and HAV Ag and peroxidase-conjugated Anti-HAV in liquid phase in an “IgM capture” principle to detect
The PanCa Monitor test uses CellMax's proprietary microfluidic platform-CMxTM to capture and enumerate tissue specific circulating tumor cells (CTCs) in 18 different cancer type, including : Colorectal, Breast, Lung, Prostate, Ovarian, Endometrial, Thyroid, Small Intestine, Pancreatic, Liver, Hepatobiliary, Bladder, Skin, Head and Neck, Esophagus, Gastric, Renal Cell Carcinoma.
DNA Repair Gene Testing
ACTBRCA®/ACTBRCA® HRD : DNA Repair Gene Testing is used to examine the genetic mutations in cancer patients for their personalized treatment plan. It is a breakthrough product to support current clinical guideline.Using next generation sequencing (NGS) to test 48 DNA Repair genes, ACTBRCA®/ACTBRCA® HRD provides opportunities to use PARP inhibitor for breast and ovarian cancers
HEPAVASE A-96 (TMB)
HEPAVASE A-96 (TMB) is a fast test for the qualitative detection of antibodies to Hepatitis A virus in serum or plasma (heparin, citrate or EDTA) specimens. This is an enzyme linked immunosorbent assay (ELISA) which utilizes HAV Ag on microtiter wells and human peroxidase-conjugated Anti-HAV in a competition principle to detect Anti-HAV levels in serum or plasma.
CellMax LBx Is Indicated For Patients With Cancer1.At DiagnosisTo look for treatable alterations (EGFR mutations) associated with Targeted (erlotinib) or Immunotherapy (pembrolizumab).When tissue is insufficient or unavailable for genomic profilingWhen only limited gene testing (NCCN-incomplete) is available30%~50% of lung cancer biopsies have insufficient/unavailable tissue for comprehensive genomic
ctDNA Detection Service
ACTMonitor® : ctDNA Detection Service is used to examine the genetic mutations in cancer patients for their personalized treatment plan. It is a breakthrough product to support current clinical guideline. Using next generation sequencing (NGS) to test 8-50 genes, ACTMonitor® can monitor cancer recurrence and treatment response.
GB HBV RealQuant™ PCR Kit
HBV RealQuantTM PCR is an in vitro nucleic acid amplification diagnostic kit developed by General Biologicals Corporation, Taiwan. It is intended for quantitative detection of hepatitis B DNA (viral load) in human serum or plasma HBV RealQuantTM PCR is not intended for use as a screening test for blood or blood products for the presence of HBV or as a diagnostic test to confirm the presence of HBV
Tumor classification traditionally is based on tissue type and organ of origin, e.g. pancreatic endocrine tumor or ductal carcinoma ofbreast. Ground breaking research in translational genomic medicine, has however shifted the paradigm towards molecular classification of tumors so the tumors are categorized based on genomic alterations in the genes driving tumorigenesis. These specific genomic alterations
Hereditary Risk Evaluation
ACTRiskTM Hereditary Risk Evaluation is used to examine hereditary cancer related genetic alterations for people with risk of hereditary cancer. Using next generation sequencing (NGS) to test 32 genes, ACTRiskTM helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with high-risk individuals.
GB HCV RealQuant™ PCR
GB HCV RealQuant™ PCR KitGB HCV RealQuant® PCR is an in vitro quantitative real-time polymerase chain reaction (qRt-PCR) kit for the determination of Hepatitils C Virus (HCV) RNA level in human serum or plasma from HCV-infected individuals.
NCCN Lung Cancer Panel
To maximize treatment options for NSCLC patients using a non-invasive and highly sensitive blood test when tissue is not available.The NCCN Lung Cancer Panel is indicated for NSCLC patients.1 in 2 PATIENTS EXPECTED TO HAVE AN ALTERATION ASSOCIATED WITH AN FDA-APPROVED TARGETED THERAPY *1 in 3 PATIENTS EXPECTED TO BE HIGH PD-L1 EXPRESSORS and ELIGIBLE FOR IMMUNOTHERAPY *** (Based on a population
Tumor Microenvironment Gene Expression Profiling
ACT TME is an RNA-based immune profiling assay that enables the characterization of tumor-immune microenvironment beyond traditional “immune-filtrated” or “non-immune-filtrated” classification, providing insights to facilitate immune-oncology drug development.
Non-Invasive Prenatal Screening, NIPS
The non-invasive prenatal screening, NIPS, which SOFIVA Genomics cooperate with illumina®, collects 10 c.c. blood from pregnant women, and extracts the cell-free fetal DNA (cffDNA) of fetus. With high throughput and analysis technique of whole genome next-generation sequencing, we have combined the chromosome database in Taiwan with global database for overall analysis. This screening technique
Non-Invasive Prenatal Screening+, NIPS+
SOFIVA Genomics collaborates with illumina®, introduces the patented technique, SAFeR™, which is win the favor of illumina®, the leading company of gene sequencing in the world, and the cooperation have started since 2015 to provide pregnant women with excellent international screening services. In Taiwan, NIPS+ is awarded National Biotechnology & Medical Care Quality Award and Symbol
Folate Metabolism Genetic Testing
According to the Health Promotion Administration of the Ministry of Health and Welfare in Taiwan, the recommended daily intake of folic acid for adults, pregnant mothers, and breastfeeding mothers is 0.4 mg, 0.8mg, and 0.5 mg, respectively.Folic Acid is Closely Related to the MTHFR GeneThe MTHFR gene is located at p36.3 on chromosome 1. When food containing folic acid is ingested, the MTHFR enzyme
Spinal Muscular Atrophy Carrier Screening
SMA is an autosomal recessive disorder, so carriers are not affected. However, when both parents are carriers, there is a 25% chance that their baby will have the disease. Approximately 95% of SMA cases are caused by the loss or conversion of large DNA segments in the SMN1 gene. The remainder of cases are likely caused by small mutations in the SMN1 gene. Most normal individuals have two or more normal
Fragile X Syndrome Carrier Screening
What is fragile X syndrome?Fragile X syndrome is a common hereditary syndrome that causes intellectual disabilities. Its incidence is 1/3600 in males and between 1/4000 and 1/6000 in females; furthermore, approximately 1/250 females are premutation carriers. Fragile X syndrome is caused by an abnormal increase in the number of CGG repeats in the FMR1 gene on position q27.3 of the X chromosome. The